Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy

• Published in: Breast cancer (Tokyo, Japan) Vol. 28; no. 5; pp. 1038 - 1050
• Main Authors: Inoue, Kenichi, Masuda, Norikazu, Iwata, Hiroji, Takahashi, Masato, Ito, Yoshinori, Miyoshi, Yasuo, Nakayama, Takahiro, Mukai, Hirofumi, van der Walt, Jan-Stefan, Mori, Joji, Sakaguchi, Sachi, Kawaguchi, Tsutomu, Tanizawa, Yoshinori, Llombart-Cussac, Antonio, Sledge, George W., Toi, Masakazu
• Format: Journal Article
• Language: English
• Published: Singapore Springer Singapore 01.09.2021; Springer
• Subjects: Adjuvant treatment; Adult; Aged; Aged, 80 and over; Aminopyridines - administration & dosage; Aminopyridines - adverse effects; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Benzimidazoles - administration & dosage; Benzimidazoles - adverse effects; Breast cancer; Cancer; Cancer Research; Care and treatment; Double-Blind Method; Epidermal growth factor; Female; Fulvestrant; Fulvestrant - administration & dosage; Fulvestrant - adverse effects; Humans; Japan; Medical research; Medicine; Medicine & Public Health; Medicine, Experimental; Middle Aged; Oncology; Original; Original Article; Quality of Life; Receptor, ErbB-2; Surgery; Surgical Oncology; Triple Negative Breast Neoplasms - drug therapy; Japan; Abemaciclib; Cyclin-dependent kinase 4 and 6 inhibitor; Breast cancer
• DOI: 10.1007/s12282-021-01239-8
• ISSN: 1340-6868

Background This was a Japanese subpopulation analysis of MONARCH 2, a double-blind, randomized, placebo-controlled, phase 3 study of abemaciclib plus fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (ABC). Methods Eligible women had progressed on (neo)adjuvant endocrine therapy (ET), ≤ 12 months from end of adjuvant ET, or on first-line ET for ABC, and had not received chemotherapy for ABC. Patients were randomized 2:1 to receive abemaciclib or placebo plus fulvestrant. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), pharmacokinetics (PK), health-related quality of life (HRQoL), and safety. Results In Japan, 95 patients were randomized (abemaciclib, n  = 64; placebo, n  = 31). At final PFS analysis (February 14, 2017), median PFS was 21.2 and 14.3 months, respectively, in the abemaciclib and placebo groups (hazard ratio: 0.672; 95% confidence interval: 0.380–1.189). Abemaciclib had a higher objective response rate (37.5%) than placebo (12.9%). PK and safety profiles for Japanese patients were consistent with those of the overall population, without clinically meaningful differences across most HRQoL dimensions evaluated. The most frequent adverse events in the abemaciclib versus placebo groups were diarrhea (95.2 versus 25.8%), neutropenia (79.4 versus 0%), and leukopenia (66.7 versus 0%). At a second data cutoff (June 20, 2019), median OS was not reached with abemaciclib and 47.3 months with placebo (hazard ratio: 0.755; 95% confidence interval: 0.390–1.463). Conclusions Results of the Japanese subpopulation were consistent with the improved clinical outcomes and manageable safety profile observed in the overall population. Clinical trial registration NCT02107703; U.S. National Library of Medicine: https://clinicaltrials.gov/ct2/show/NCT02107703 .